Table 2 A Distribution of the 93 patients included in the study according to the maximum degree of severity reached; B Distribution of the samples obtained in the three evolutionary phases, according to time from symptom onset, of the total number of patients (93 patients, 201 samples) and of the patients followed longitudinally, with at least two samples in two consecutive evolutionary phases (72 patients, 180 samples)
From: IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes
A | ||||
|---|---|---|---|---|
CCDC scale | Mild-moderate | Severe | Critical | Total |
Patients (n) | 51 | 15 | 27 | 93 |
WHO OS | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
Patients (n) | 0 | 0 | 7 | 41 | 20 | 1 | 5 | 19 | 93 |
B | ||||
|---|---|---|---|---|
Illness onset | 1–9 days | 10–16 days | ≥ 17 days | Total |
93 patient samples (n) | 97 | 59 | 45 | 201 |
72 patient samples (n) | 87 | 53 | 40 | 180 |